SOX方案在进展期胃癌患者中的临床疗效观察  

Effect observation of SOX regimen on patients with advanced gastric cancer

作　　者：宋红蕾[1] 毕延智[1] 徐珍[1] 董益忠[1] 张亚平[1] 盛桂凤[1] 胡岳棣[1] 

机构地区：[1]苏州大学附属常州肿瘤医院肿瘤内科,江苏常州213001

出　　处：《实用临床医药杂志》2012年第23期20-22,共3页Journal of Clinical Medicine in Practice

基　　金：中国高校医学期刊临床专项资金(11220247)

摘　　要：目的探讨SOX方案在进展期胃癌中的临床疗效及安全性评价。方法进展期胃癌患者46例随机分为SOX组和对照组,各23例。SOX组给予SOX方案治疗,对照组给予EOF方案治疗。观察2组患者近期疗效、不良反应发生情况;治疗后KPS评分。结果 2组有效率、临床获益率、毒副反应发生率无显著差异(P>0.05)。SOX组治疗后KPS评分为(86.4±7.9)分,改善率为68.2%。对照组治疗后KPS评分为(79.4±7.5)分,改善率为34.8%。2组KPS评分及改善率差异有统计学意义(P<0.01)。结论 SOX方案治疗进展期胃癌临床受益率较高,不良反应较轻,耐受性良好,值得临床进一步应用观察。Objective To explore the clinical curative effect and safety evaluation of SOX regimen on patients with advanced gastric cancer. Methods 46 patients with advanced gastric can- cer were randomly divided into SOX group and control group, 23 cases in each group. SOX group was given SOX regimen, and the control group was given EOF regimen. Curative effect and adverse reactions were observed in 2 groups; KPS score was made after treatment. Results Efficiency, clinical benefit rate and adverse reaction rate between 2 groups had no significant difference （P ;〉0. 05）. The KPS score of the SOX group after treatment was （86.4-＋ 7.9） points, the improvement rate was 68.2%. The KPS score of the control group after treatment was （79.4 __- 7.5） points, the improvement rate was 34.8 %. There were statistical differences in the KPS score and improvement rate beween 2 groups （P〈0.01）. Conclusion SOX regimen has a higher clinical benefit rate, mild adverse reactions, well toleration in treating patients with advanced gastric cancer, and it is worthy of application and further clinical observation.

关 键 词：SOX方案 进展期胃癌 临床疗效 毒副反应 

分 类 号：R735.2[医药卫生—肿瘤]